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AbstrAct
background To validate a short cognitive test: the 
Test Your Memory for Mild Cognitive Impairment 
(TYM-MCI) in the diagnosis of patients with amnestic 
mild cognitive impairment or mild Alzheimer’s disease 
(aMCI/AD).
Methods Two hundred and two patients with mild 
memory problems were recruited. All had ’passed’ 
the Mini-Mental State Examination (MMSE). Patients 
completed the TYM-MCI, the Test Your Memory test 
(TYM), MMSE and revised Addenbrooke’s Cognitive 
Examination (ACE-R), had a neurological examination, 
clinical diagnostics and multidisciplinary team review.
results As a single test, the TYM-MCI performed as well 
as the ACE-R in the distinction of patients with aMCI/
AD from patients with subjective memory impairment 
with a sensitivity of 0.79 and specificity of 0.91. Used in 
combination with the ACE-R, it provided additional value 
and identified almost all cases of aMCI/AD. The TYM-MCI 
correctly classified most patients who had equivocal ACE-R 
scores. Integrated discriminant improvement analysis 
showed that the TYM-MCI added value to the conventional 
memory assessment. Patients initially diagnosed as 
unknown or with subjective memory impairment who were 
later rediagnosed with aMCI/AD scored poorly on their 
original TYM-MCI.
conclusion The TYM-MCI is a powerful short cognitive 
test that examines verbal and visual recall and is a 
valuable addition to the assessment of patients with 
aMCI/AD. It is simple and cheap to administer and 
requires minimal staff time and training.
IntroductIon 
Early accurate diagnosis of Alzheimer’s disease 
(AD) is a major global health priority.1 Early diag-
nosis is important for patients and helps plan care. 
Emerging disease-modifying treatments for AD are 
likely to halt disease progression rather than reverse 
changes, so it is becoming critical to identify AD 
early. Patients with AD typically present with symp-
toms caused by poor recall of recently learnt visual 
and verbal material; clinical testing reveals episodic 
memory deficits.2 3 Patients presenting with these 
symptoms and signs are diagnosed as having 
amnestic mild cognitive impairment (aMCI) if their 
problems are mild (with intact functional abilities)4 
or probable AD if they have problems which impact 
on their lives.5 Many patients with aMCI progress 
to AD6 and patients with a diagnosis of aMCI or 
mild AD form a continuum, so we consider them as 
one group: aMCI/AD.
The diagnosis of cognitive disease requires a 
history from the patient and an informant, an 
examination including short cognitive tests and 
investigation.7 Short cognitive tests can be divided 
into three groups: orientation-dominated question-
naires, highly selective tests and multidomain tests.8 
Multidomain tests are the most useful in aiding 
diagnosis.8 The most widely used short cognitive 
tests in memory clinics include the Addenbrooke’s 
Cognitive Examinations (ACE-R).9 10
A clinical assessment including a multidomain 
cognitive test usually enables diagnosis in patients 
with moderate AD. In milder cases, the diagnosis of 
AD is more difficult and may remain unclear after 
initial assessment. There are several methods avail-
able to clarify the diagnosis in mild cases including 
expert neuropsychological assessment, cerebrospinal 
fluid biomarkers, structural and functional brain 
imaging (including amyloid positron emission tomog-
raphy). These are useful but share disadvantages: 
they require referral to specialists, take time and 
are expensive. This limits them to specialist services 
within highly developed countries. This study exam-
ines whether a targeted short cognitive test examining 
visual and verbal recall could be a cheap, effective 
method of supporting a diagnosis of aMCI/AD.
Some current multidomain short cognitive tests 
such as the ACEs,9 10 Montreal Cognitive Assessment 
(MOCA)11 and the Test Your Memory (TYM)12 13 
are useful in patients with aMCI, but these tests are 
designed for several purposes and do not test visual 
recall (a cognitive skill affected early in AD). The 
Test Your Memory for Mild Cognitive Impairment 
(TYM-MCI), formerly named the H-TYM, was 
designed to test verbal and visual recall to optimise 
its sensitivity to aMCI/AD. The TYM-MCI is shown 
in online supplementary appendix 1.
In the validation study, the TYM-MCI was shown 
to be very powerful in distinguishing patients with 
mild AD from normal controls with excellent sensi-
tivity (0.95) and specificity (0.93).14 This study 
examines the performance of the TYM-MCI in 
the more demanding and clinically relevant task 
of distinguishing patients with aMCI/AD from 
patients with subjective memory complaints (SMC) 
without neurological disease (for example, patients 
diagnosed as worried well or depressed).
MAterIAls And Methods
setting
Patients were enrolled from a UK memory clinic 
between March 2011 and March 2014. A prospec-
tive cohort design was used to compare the 
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TYM-MCI with the clinical diagnosis in patients supported 
as indicated by imaging, neuropsychological assessment and 
follow-up. Patients were recruited prospectively on a conve-
nience basis—when nurses had time. The 96 patients with SMC 
and 58 patients with aMCI/AD recruited in this study provide 
84% power to detect a difference of 2 points in the TYM-MCI 
score assuming a two-sided 5% significance level and a SD of 4 
based on a previous study.12
Patients were seen by a consultant neurologist and/or psychi-
atrist. All had a physical examination and completed the 
ACE-R, Mini-Mental State Examinations (MMSE),15 TYM test 
and TYM-MCI. The diagnoses of AD and aMCI were made 
according to current diagnostic criteria4 5 and were agreed at 
a multidisciplinary team (MDT) meeting; other diagnoses were 
made by consensus at the MDT. The specialist and the MDT 
had access to the ACE-R score but not the TYM or TYM-MCI. 
Follow-up and investigations were determined on clinical need 
at the MDT meeting; 57% of the patients were followed up for 
between 4 months and 3 years. To select patients with mild prob-
lems, those scoring ≤24/30 on the MMSE were excluded.
Ethical permission for the study was obtained from 
Cambridgeshire 2 Ethics Committee.
Patients were divided into six diagnostic groups:
1. SMC
2. aMCI/AD
3. No clear diagnosis
4. Fixed memory deficit head injury
5. Neurological disease sometimes associated with cognitive 
problems, for example, epilepsy
6. Other degenerative dementia
The analysis focuses on groups 1 and 2. Patients with mild 
non-amnestic cognitive problems were included in groups 3 to 5 
rather than treated as a separate group.
Administering and scoring the tYM-McI
The TYM-MCI was assessed in five ways:
1. As a single test in the diagnosis of aMCI/AD.
2. As a combined assessment with the ACE-R.
3. In patients with equivocal ACE-R scores.
4. Whether it adds value to the normal memory clinic 
assessment.
5. As a predictor of patients initially reassured but who are later 
rediagnosed with aMCI/AD.
The ordinary TYM test was also administered. To avoid 
confusion between the tests, the performance of the TYM test is 
in online supplementary appendix 2.
The TYM-MCI was printed on both sides of a sheet of card 
(see online supplementary appendix 1).
The TYM-MCI was supervised by a nurse in a quiet room. 
Training the nurses took 5 min. The patient was asked to copy 
the diagram and read the passage silently and then aloud. The 
patient answered the page 1 questions referring back to the 
passage. The patient was not told to memorise the answers. The 
card was turned over and the patient was asked to:
 ► reproduce the diagram within the square
 ► answer the same questions
 ► circle flowers mentioned in the passage
 ► answer new questions concerning the passage.
scoring
Five page 2 recall tasks were scored:
1. Recall of the drawing           /15
2. Recall of page one answers          /5
3. Recognition of flowers from the passage   /4
4. No flower misrecognition          /2
5. Answering new questions on the passage    /4
6. Total                    /30
The page two score=TYM-MCI score. Verbal recall 1 is the 
recall of answers already given, and verbal recall 2 is the new 
answers.
The cut-off of ≤13/30 optimised in the validation study14 
was used. The TYM-MCI, TYM and ACE-R were scored by the 
nurses with access to some clinical information.
statistical methods
Cronbach’s alpha was calculated for the TYM-MCI.
The distribution of the test scores did not follow a normal 
distribution so the Mann-Whitney U test was applied to compare 
between groups. Data from patients with SMC and aMCI/AD 
were used to plot a receiver operating characteristic (ROC) 
curve. Sensitivities, specificities and predictive values were 
calculated using standard methods. An ‘or’ rule was used for 
combined ROC analysis of the ACE-R and TYM-MCI. Correla-
tions between the TYM-MCI and ACE-R were calculated using 
Spearman’s r coefficient for non-parametric data.
To produce the age-matched groups, an age range of 51–80 
years was set. The median value was obtained for each group, 
and all cases above the median were included for the SMC group 
and all cases below the median were included for the aMCI/AD 
group. Cases were then randomly sampled from the remaining 
cases to form equal sample sizes of 50.
To determine whether the TYM-MCI provided additional 
information to standard tests, logistic regression was used to 
assess predictive ability. A logistic regression model was fitted 
to outcome (aMCI/AD or SMC) adjusting for age, MMSE and 
ACE-R. The integrated discriminant improvement16 was calcu-
lated to assess the improvement in model performance when 
the TYM-MCI is included compared with when it is excluded. 
Additional ROC curves were plotted using the predictive values 
generated from the models.
table 1 Characteristics and performance of the six groups on short cognitive tests including mean scores and SD
Group diagnosis Patients (n) Mean age MMse/30 Ace-r/100 tYM-McI/30
1 SMC 96 59.2 (SD 9.2) 28.6 (SD 1.1) 90.8 (SD 5.5) 19.8 (SD 5.0)
2 aMCI/AD 58 67.8 (SD 7.4) 26.8 (SD 1.5) 81.3 (SD 5.3) 9.4 (SD 4.6)
3 No clear diagnosis 13 66.5 (SD 8.6) 27.1 (SD 1.7) 82.0 (SD 6.4) 14.9 (SD 4.6)
4 Fixed deficits 11 61.7 (SD 8.8) 27.6 (SD 1.5) 84.0 (SD 6.0) 13.4 (SD 7.4)
5 Other neurological disease 12 61.9 (SD 9.8) 28.5 (SD 1.4) 88.2 (SD 6.0) 16.8 (SD 5.6)
6 Non-AD dementia 10 66.6 (SD 12.5) 27.4 (SD 1.7) 82.8 (SD 7.1) 14.0 (SD 4.3)
ACE-R, Addenbrooke’s Cognitive Examinations; aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease; MMSE, Mini-Mental State Examinations; SMC, subjective 
memory complaints; TYM-MCI, Test Your Memory for Mild Cognitive Impairment.
group.bmj.com on October 5, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
3Brown JM, et al. J Neurol Neurosurg Psychiatry 2017;0:1–7. doi:10.1136/jnnp-2016-315327
cognitive neurology
results
Patient characteristics
Two hundred and two patients aged between 40 years and 80 
years were enrolled. Two patients (one with SMC, one with 
aMCI) failed to complete the tests and were excluded. The char-
acteristics of the remaining 200 are shown (table 1). There were 
no adverse events. Patients gave informed consent. The patients 
were divided into the six groups described, but principal anal-
yses were restricted to the SMC and aMCI/AD groups in keeping 
with the primary aim of the study. The SMC patients formed 
the largest group with a mean age of 59.2 years, significantly 
lower than aMCI/AD patients (mean age 67.8 years). Therefore, 
additional analyses were performed on age-matched subsamples 
from the SMC and aMCI/groups.
reliability of the tYM-McI
Cronbach’s alpha was 0.89 showing high internal consistency of 
the TYM-MCI.
The TYM-MCI and ACE-R as single tests to distinguish patients who 
have aMCI/AD from patients with SMC
Both the TYM-MCI and ACE-R detected a significant differ-
ence between patients with aMCI/AD and patients with SMC; 
the differences were proportionally larger in the TYM-MCI than 
the ACE-R (table 2). Effect size shows a proportionally larger 
difference for the visual recall task and the overall TYM-MCI 
score compared with the ACE-R. Spearman’s rho coefficient for 
non-parametric data was 0.66 (p<0.001) showing a moderately 
high correlation between the TYM-MCI and ACE-R.
The difference between patients with SMC and patients 
with aMCI/AD on the TYM-MCI is shown in figure 1. There is 
a clear separation of most individuals: only patients with SMC 
scored ≥20 and only patients with aMCI/AD scored ≤8. The 
ROC curve (figure 2) compares the ability of the TYM-MCI, 
ACE-R and MMSE to distinguish patients with aMCI/AD from 
those with SMC. Sensitivities, specificities, positive predica-
tive value (PPV) and negative predicative value (NPV) for the 
TYM-MCI and ACE-R are shown in table 3.
All tasks showed a significant difference between SMC patients 
and aMCI/AD patients (table 2). The largest difference was for 
visual recall as in the original study.14
Analysis of age-matched groups
As there was a significant difference in age between the SMC 
and aMCI/AD groups, further analyses were performed using 
age-matched cohorts (table 4 and 5). Non-parametric Mann-
Whitney U test showed no significant difference in the ages of 
the revised groups (SMC average age 64.4 years, aMCI/AD 66.7 
years p=0.23)
The area under the curve (AUC) of the ROC curve was 0.91 
(95% confidence limit (Cl) 0.86 to0.96) for the TYM-MCI, 
table 2 Comparison of the performance of the ACE-R, TYM-MCI subtests and TYM-MCI scores using effect size from a two-sample t-test and 
Mann-Whitney U test p value in patients with aMCI/AD and those with SMC
subjective memory complaints 
(mean (sd))
Amnestic McI/mild Ad (mean 
(sd)) effect size* p Value Mann-Whitney u test
ACE-R 90.8 (5.5) 81.3 (5.3) 11.0 <0.001
Overall TYM-MCI 19.8 (5.0) 9.4 (4.6) 13.0 <0.001
Visual recall 9.8 (3.3) 2.9 (3.1) 13.0 <0.001
Verbal recall 1 4.4 (0.9) 3.1 (1.1) 8.5 <0.001
Verbal recall 2 5.5 (2.4) 3.4 (2.2) 5.4 <0.001
*Mean difference divided by SE (effect size from a two sample t-test).
ACE-R, Addenbrooke’s Cognitive Examinations; AD, Alzheimer’s disease, aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease; TYM-MCI, Test Your Memory for 
Mild Cognitive Impairment.
Figure 1 Box plot showing the distribution of the TYM-MCI score 
for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive 
impairment or Alzheimer’s disease; SMC, subjective memory complaints; 
TYM-MCI, Test Your Memory for Mild Cognitive Impairment.
Figure 2 ROC curve for the TYM-MCI, ACE-R and MMSE in the 
separation of patients with aMCI/AD from those with SMC. ACE-R, 
Addenbrooke’s Cognitive Examinations; aMCI/AD, amnestic mild cognitive 
impairment or Alzheimer’s disease; MMSE, Mini-Mental State Examinations; 
TYM-MCI, Test Your Memory for Mild Cognitive Impairment.
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compared with 0.89 (95% Cl 0.78 to 0.96) for the ACE-R. 
Using the cut-off of ≤13, the sensitivity was 0.78 (95% Cl 0.65 
to 0.88) and specificity 0.89 (95% Cl 0.78 to 0.96). This resulted 
in a PPV of 0.88 (95% Cl 0.75 to 0.95) and a NPV of 0.80 (95% 
Cl 0.68 to 0.89) for the TYM-MCI.
Analysis of the TYM-MCI and ACE-R in combination
The cross-classification of TYM-MCI and ACE-R scores against 
the clinical diagnosis is shown (table 6). Combining the results of 
the TYM-MCI with the ACE-R with an ‘or’ rule, the tests show 
a superior performance to either test alone. Using the criteria of 
scoring ≤82 on the ACE-R or scoring ≤13 on the TYM-MCI 
then the results are excellent with a sensitivity of 88% (95% Cl 
77% to 95%) and specificity of 85% (95% Cl 77% to 92%). 
Where it is crucial that no cases of aMCI/AD are missed then 
combining the ACE-R (cut-off 87) with the TYM-MCI yields a 
sensitivity of 97% (95% Cl 88% to 100%).
Analysis of TYM-MCI in patients with equivocal ACE-R scores
The analysis on the 32 patients with equivocal ACE-R scores 
(83–87) showed that the TYM-MCI was very useful in this group. 
Mean score on the TYM-MCI was 17.2 for patients with SMC, 
9.9 for patients with aMCI/AD. Eleven of fourteen patients with 
SMC and equivocal ACE-R scores passed the TYM-MCI. Thir-
teen of eighteen patients with aMCI/AD with equivocal ACE-R 
scores were detected by the TYM-MCI. The visual recall task 
was particularly useful (mean score 8.2 in patients with SMC, 
3.2 in patients with aMCI/AD). The AUC of the ROC was 0.85 
with a sensitivity of 0.72 and specificity of 0.79 (cut-off ≤13). 
Using a cut-off of ≤18, all cases of aMCI/AD with equivocal 
ACE-R scores were detected by the TYM-MCI.
The TYM-MCI as an additional test to the ACE-R
Logistic regression analysis with integrated discriminant 
improvement analysis (table 7) showed that the TYM-MCI score 
is a highly significant predictor of the diagnosis of aMCI/AD 
(p<0.0001) even after adjusting for the ACE-R score, MMSE 
and age. With model calibration, the logistic regression model 
which includes the TYM-MCI score confers an advantage over 
the model excluding the TYM-MCI: Nagelkerke’s R2 statistic 
increased from 0.70 to 0.77 after including the TYM-MCI score 
and the Hosmer-Lemeshow χ2 statistic decreased from 8.02 
(p=0.43) to 5.52 (p=0.70). ROC curves were plotted based on 
the model predictive values for each of the models. The AUC was 
0.96 (Cl 0.94 to 0.99) for the model including the TYM-MCI 
score, compared with 0.93 (95% Cl 0.90 to 0.97) for the model 
without the TYM-MCI.
Integrated discriminant improvement (IDI) was used16 to 
quantify the significance of this difference using the new model 
including the TYM-MCI compared with the model without the 
TYM-MCI. The IDI was 0.10 (95% confidence limits 0.05 to 
0.16, p<0.001) showing that the TYM-MCI provides a signifi-
cant improvement in model performance.
AnAlYsIs oF PAtIents In WhoM the dIAGnosIs 
WAs chAnGed to AMcI/Ad
Thirteen patients diagnosed as SMC or unknown were subse-
quently rediagnosed with aMCI/AD (10 were under follow-up, 
3 re-referred). These patients had significantly lower scores 
on their baseline TYM-MCI and ACE-R compared with all 
patients with SMC (table 8), they performed particularly 
poorly on visual recall.
table 3 Sensitivity and specificity of the ACE-R and TYM-MCI
specificity sensitivity
False negatives 
(n) False positives (n) PPV nPV
Auc of continuous 
score
ACE-R≤82 0.92 (0.84–0.96) 0.59 (0.45–0.71) 24 8 0.81 (0.66–0.91) 0.79 (0.70–0.86) 0.89 (0.84–0.94)
ACE-R≤87 0.77 (0.67–0.85) 0.90 (0.79–0.96) 6 22 0.70 (0.59–0.80) 0.92 (0.84–0.97) 0.89 (0.84–0.94)
TYM-MCI≤13 0.91 (0.83–0.96) 0.79 (0.67–0.89) 12 9 0.84 (0.71–0.92) 0.88 (0.80–0.94) 0.93 (0.89–0.97)
95% confidence limits in brackets.
ACE-R, Addenbrooke’s Cognitive Examinations; AUC, area under the curve; NPV, negative predicative value; PPV, positive predicative value; TYM-MCI, Test Your Memory for Mild 
Cognitive Impairment.
table 4 Comparison of age-matched groups
short cognitive test or subtest
Patients with subjective memory 
complaints (mean (sd))
Patients with aMcI/Ad (mean 
(sd)) effect size*
p score Mann-Whitney 
u test
ACE-R 91.1 (5.4) 81.4 (5.5) 9.4 p<0.001
Total TYM-MCI 19.3 (5.2) 9.5 (4.7) 10.3 p<0.001
Visual recall 9.4 (3.3) 3.1 (3.2) 10.3 p<0.001
Verbal recall 1 4.3 (1.2) 3.1 (1.1) 6.0 p<0.001
Verbal recall 2 5.5 (2.6) 3.4 (2.2) 4.6 p<0.001
*Mean difference divided by standard error (effect size from a two sample t-test).
ACE-R, Addenbrooke’s Cognitive Examinations; aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease; TYM-MCI, Test Your Memory for Mild Cognitive Impairment.
table 5 Sensitivity and specificity of the ACE-R and H-TYM in age-matched patients. 95% confidence limits in brackets
specificity sensitivity
False 
negatives (n)
False 
positives (n) PPV nPV
Auc of continuous 
score
ACE-R≤82 0.91 (0.80 to 0.97) 0.56 (0.42 to 0.70) 24 5 0.86 (0.71 to 0.95) 0.68 (0.56 to 0.78) 0.90 (0.84 to 0.96)
ACE-R≤87 0.82 (0.69 to 0.91) 0.89 (0.78 to 0.96) 6 10 0.83 (0.71 to 0.92) 0.88 (0.76 to 0.96) 0.90 (0.84 to 0.96)
TYM-MCI≤13 0.89 (0.78 to 0.96) 0.78 (0.65 to 0.88) 12 6 0.88 (0.75 to 0.95) 0.80 (0.68 to 0.89) 0.91 (0.86 to 0.96)
ACE-R, Addenbrooke’s Cognitive Examinations; NPV, negative predicative value; PPV, positive predicative value; TYM-MCI, Test Your Memory for Mild Cognitive Impairment.
group.bmj.com on October 5, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
5Brown JM, et al. J Neurol Neurosurg Psychiatry 2017;0:1–7. doi:10.1136/jnnp-2016-315327
cognitive neurology
dIscussIon
The TYM-MCI is a targeted short cognitive test designed for a 
single purpose—the identification of aMCI/AD. The TYM-MCI 
is free, easy and quick to use and requires minimal training to 
administer. A previous study showed that the TYM-MCI was 
very powerful at distinguishing patients with aMCI/AD from 
healthy controls with an AUC of the ROC of 0.99.14 This study 
showed that the TYM-MCI performed very well on the useful 
and challenging task of distinguishing patients with aMCI/AD 
from those with SMC (with diagnoses such as worried well, 
depression, anxiety and functional problems) with an AUC of 
0.93.
A new cohort of patients attending a memory clinic who 
‘passed’ the MMSE was recruited. The performance of the 
TYM-MCI in the diagnosis of aMCI or mild AD was assessed in 
comparison with and in combination with the ACE-R. The direct 
comparison of the tests needs to be interpreted with caution as 
there are two biases: first, the ACE-R and MMSE were available 
to the clinician whereas the TYM-MCI was not and second only 
patients who passed the MMSE were included. The first of these 
confounding factors may favour the ACE-R as the result will 
influence the specialist. The second precluded a direct compar-
ison with the MMSE noting that it is well established that the 
MMSE is insensitive to aMCI/AD.12 17 18 Patients were recruited 
in this study when there was sufficient time for nurses to admin-
ister tests, which could introduce a selection bias.
Clinicians were often uncertain of the diagnosis initially in this 
difficult group, but where the balance of evidence from clinical 
assessment, investigations and follow-up favoured aMCI/AD or 
SMC, this was recorded. The mean MMSE score of 26.8 in the 
aMCI/AD group was high, confirming that patients had mild 
disease. The TYM-MCI showed a complete separation of aMCI/
AD and SMC for patients with scores below 8 and above 20. 
The ACE-R also performed well in this study. There were larger 
differences between the groups on the TYM-MCI compared with 
the ACE-R: the TYM-MCI scores of aMCI/AD patients were 
53% of the TYM-MCI scores of SMC patients compared with a 
10% difference in the ACE-R score. The largest difference was in 
visual recall. Calculation of the effect size showed better perfor-
mance of the TYM-MCI and the visual recall subtest compared 
with the ACE-R in distinguishing aMCI/AD from SMC.
Neuropsychological profiles of AD show that the character-
istic earliest features of mild AD are poor recall of recently learnt 
visual and verbal material and these can be present and appear 
stable for years in the ‘pre-dementia’ stage of AD pathology.19 
Although two short tests that are used occasionally test visual 
recall, the Mini-Mental Parkinson’s20 and the visual association 
test,21 visual recall is often ignored in the clinical assessment of 
suspected AD. The TYM-MCI is the first short cognitive test to 
test both visual and verbal recall making it a suitable instrument 
to detect disease in this important group of patients.
Additional analyses performed with age-matched sub-groups 
from patients with aMCI/AD and SMC showed that the differ-
ences remained highly significant for all the TYM-MCI subtests 
with similar effect sizes, PPV and ROC curve. Logistic regression 
analysis confirmed that the TYM-MCI result remained signifi-
cant after adjusting for age.
Addition of the TYM-MCI result to the ACE-R (cut-off 87) 
improves its performance: only 2 of the 58 aMCI/AD patients 
passed both tests and only 6 of the 96 SMC patients failed both 
tests.
Examining the usefulness of the TYM-MCI in the 32 patients 
with equivocal ACE-R scores showed it performed very well 
with a high AUC, sensitivity and specificity in distinguishing 
such patients with aMCI/AD from those with SMC. Logistic 
regression analysis showed that the TYM-MCI score was a 
highly significant predictor of aMCI/AD (p<0.0001) even after 
adjusting for ACE-R, MMSE scores and age. The integrated 
discriminant improvement showed that using the TYM-MCI 
table 6 Mean scores of the ACE-R cross-classified against the TYM-
MCI and the final diagnosis of subjective memory complaint 
tYM-McI score
0–13 14+ total
(A) Patient with SMC
ACE-R score 0–82 3 5 8
83–87 3 11 14
88+ 3 71 74
Total 9 87 96
(B) Patient with aMCI/AD
ACE-R score 0–82 29 5 34
83–87 13 5 18
88+ 4 2 6
Total 46 12 58
ACE-R, Addenbrooke’s Cognitive Examinations; aMCI/AD, amnestic mild cognitive 
impairment or Alzheimer’s disease; SMC, subjective memory complaint; TYM-MCI, 
Test Your Memory for Mild Cognitive Impairment.
table 7 Logistic regression analysis to assess the predictive ability of 
the TYM-MCI, MMSE, ACE-R and age
or 95% cI p Value
TYM-MCI score 0.75 0.65 to 0.86 p<0.0001
MMSE 0.82 0.47 to 0.97 p=0.51
ACE-R 0.85 0.75 to 0.97 p=0.017
Age 1.12 1.04 to 1.20 p=0.002
ACE-R, Addenbrooke's Cognitive Examinations; MMSE, Mini-Mental State 
Examinations; TYM-MCI, Test Your Memory for Mild Cognitive Impairment.
table 8 Mean baseline scores for the patients whose diagnosis changed to aMCI/AD compared with patients in group 1 (SMC)
short cognitive test or 
subtest
Mean scores of patients whose diagnosis 
changed to aMcI/Ad (n=13)
subjective memory
complaints (n=96) effect size*
p score Mann-Whitney 
u test
ACE-R 83.5 (4.4) 90.8 (5.5) 4.6 p<0.001
Total TYM-MCI 9.8 (4.7) 19.8 (5.0) 6.9 p<0.001
Visual recall 3.4 (2.9) 9.8 (3.3) 6.6 p<0.001
Verbal recall 1 2.7 (1.3) 4.4 (0.9) 6.2 p<0.001
Verbal recall 2 3.7 (2.2) 5.5 (2.4) 2.5 p=0.02
*Mean difference divided by standard error (effect size from a two sample t-test).
ACE-R, Addenbrooke's Cognitive Examinations; aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease; SMC, subjective memory complaint; TYM-MCI, Test Your 
Memory for Mild Cognitive Impairment.
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provides a significant improvement in model performance 
compared with a model that used age, MMSE and ACE-R only.
In this study, the TYM-MCI has a sensitivity of 0.79. Therefore, 
used alone it will not detect some cases of aMCI/AD. Using the 
TYM-MCI with the ACE-R improves the sensitivity or increasing 
the TYM-MCI cut-off to 16/30 increases the sensitivity to 0.93.
Patients diagnosed with SMC are a heterogeneous group 
including patients with no organic disease, psychiatric problems 
or other diseases. A few patients with an original diagnosis of 
SMC later present with aMCI/AD: 13 patients in this study who 
were initially felt not to have aMCI/AD were later diagnosed 
with it. These 13 individuals scored significantly lower than 
other SMC patients on all subtests of the TYM-MCI (partic-
ularly visual recall). A low score on the TYM-MCI cautions 
against diagnosing SMC.
The scores on the TYM-MCI in the most difficult patients—
those with equivocal ACE-R scores and patients whose diagnosis 
changed were similar to those of the whole aMCI/AD cohort. 
This suggests that the TYM-MCI score may fall early in the 
disease and then plateau. This corresponds with physiological 
and anatomic studies which show severe involvement of hippo-
campal and parahippocampal structures early in the disease 
prior to AD pathology spreading to other areas.19 This suggests 
the TYM-MCI may detect aMCI/AD prior to the development 
of a generalised dementia.
Another study has examined the use of the TYM-MCI in a 
memory clinic.22 The TYM-MCI was administered to 38 patients 
in whom the diagnosis of MCI or subjective memory impairment 
was uncertain. With a cut-off of 15/30, the TYM-MCI proved 
very sensitive for detecting MCI when the diagnosis was unclear, 
the author concluded that the TYM-MCI was useful in the 
assessment of such patients.
The current study has several limitations: the recruitment 
period of this study overlapped with an earlier study.14 The two 
studies had different inclusion criteria but patients with aMCI/
AD could be recruited into either. There was no dual recruit-
ment but not all patients meeting criteria were recruited into this 
study. Based on a comparison of results from the studies if all 
aMCI/AD patients had been included in this study it would have 
increased the number of patients in the aMCI/AD group and 
lowered the TYM-MCI scores of the aMCI/AD cohort further 
increasing the power and observed effect sizes. Nonetheless, this 
study was adequately powered.
The interpretation of cognitive tests depends on the clinical 
setting. This study was performed in a NHS clinic and patients 
were managed by experienced memory specialists according to 
their usual practice. This makes the results applicable to similar 
settings but there was some variation in investigative prac-
tice. The patients were diagnosed clinically with support from 
neuroimaging, neuropsychological assessment and follow-up in 
selected individuals. Use of cerebrospinal fluid (CSF) biomarkers 
and more specialised functional and structural imaging could 
support the clinical diagnosis but were not practical to use in all 
subjects. The diagnosis of aMCI/AD was based on international 
consensus criteria rather than biomarkers.
In summary, the TYM-MCI performs at least as well as the 
ACE-R as a cognitive test in distinguishing patients with mild 
aMCI/AD from those with SMC. Further studies are needed to 
directly compare the TYM-MCI with other short cognitive tests 
such as the MOCA11 and Qmci.23 The TYM-MCI is useful in 
the diagnosis aMCI/AD in patients with equivocal ACE-R scores 
and in aMCI/AD patients initially diagnosed as having SMC or 
unknown. Uniquely among short cognitive tests the TYM-MCI 
examines visual and verbal recall. The TYM-MCI shows a 
consistent pattern with very low scores on visual recall and low 
scores on verbal recall even in the mildest patients. It adds value 
to the ACE-R. Very few patients with aMCI/AD pass both tests 
and very few patients with SMC fail both tests. Importantly for 
clinicians the TYM-MCI is free, quick and easy to use. It takes 
5 min to learn how to administer the TYM-MCI. The TYM-MCI 
is a very useful aid in the diagnosis of aMCI/AD, alone or in 
combination with the ACE-R. The TYM-MCI will be available 
to download free from the website  tymtest. com.
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